<?xml version="1.0" encoding="UTF-8"?>
<p>While interventions available for sepsis and severe trauma are limited to fluid resuscitation and antibiotics, immunomodulatory mechanisms remain the major targets for thedevelopment of effective therapies. Perhaps, successful completion of a clinical trial for PD-L1 in sepsis could also be tested as a therapy for COVID-19â€“related immunosuppression. Given results obtained by Spinetti et al,
 <sup>
  <xref rid="R1" ref-type="bibr">1</xref>
 </sup> this seems to be a relevant approach to diminishing morbidity and mortality among ICU patients with COVID-19. Another potential benefit is utilization of HLA-DR variants as a prognostic tool to identify individuals with a higher risk for severe infection and hospitalization due to COVID-19.
</p>
